Preeclampsia
Conditions
Interventions
Sponsors
Sakina Ghazali
Eligibility
Sex/Gender
Female
Inclusion criteria
Inclusion criteria: 1. Severe hypertension (systolic blood pressure of 160mmHg or more and /or diastolic blood pressure of 110mmHg or more) and Proteinuria of 2+ or more as measured by dipstick in a catheter specimen urine sample. 2. Pregnancy = 28 weeks gestation. 3. Singleton pregnancy. 4. Live fetus with normal fetal heart rate.
Exclusion criteria
Exclusion criteria: 1. Medical disorders like asthma, cardiac failure, heart block, cardiac arrhythmias. 2. Contraindication or known allergy to hydralazine or labetalol neurological disease. 3. Fetal congenital abnormality. 4. Women who refuse consent. 5. Referrals already on anti-hypertensive.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Primary outcome Number of doses/ total dosage, unit drop in systolic blood pressure and diastolic blood pressure after each administered dose, time to achieve target of blood pressure which is systolic blood pressure of 140–150 mmHg and diastolic blood pressure of 90–100 mmHg as end point of effectiveness and non-attainment of target blood pressure after stipulated maximum dosage. | — |
Secondary
| Measure | Time frame |
|---|---|
| 1 Persistent severe hypertension and requirement of additional drug to control blood pressure. 2 Medication-related undesirable effects on both mother and baby. | — |
Countries
Nigeria
Contacts
Public ContactNana Madugu
Professor
Outcome results
None listed